THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to ...

By Deena Beasley (Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S ...

Amgen will invest $900 million to expand its New Albany manufacturing facility and add 350 jobs in what is the largest life sciences and pharmaceutical manufacturing expansion in the history of Ohio.

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. production presence with plans for a major upgrade at its plant in central ...

April 25 (Reuters) - Amgen (AMGN.O), opens new tab on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging ...

Amgen Inc. will invest $900 million to expand an Ohio manufacturing facility, the latest drug company to promise increased US production as the White House presses forward with tariffs on ...

NEW ALBANY, Ohio — Biotechnology company Amgen announced a $900 million expansion of its New Albany facility on Friday. The expansion will add 350 new jobs in central Ohio. Several leaders spoke ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

(Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of $329.00. The company’s shares closed yesterday ...